Answers are grounded in this paper and cite their sources.
This joint statement provides the first national consensus guidance for standardising lipid testing and reporting across UK laboratories to improve cardiovascular risk assessment.
Atherosclerotic cardiovascular disease remains a major cause of premature death in the United Kingdom. Lipid testing is a key tool used to assess cardiovascular risk and guide clinical management decisions. There are currently no national guidelines to provide evidence-based recommendations on lipid testing and reporting for UK laboratories and clinicians. Here we present consensus guidance, following a review of published evidence by a multidisciplinary group of UK experts across a range of laboratory and clinical services. Recommendations include the composition of a standard lipid profile; indications for, and composition of, an enhanced lipid profile including apolipoprotein B and lipoprotein (a); use of the Sampson-NIH calculation for LDL-c estimation and guidance on when to flag abnormal results. This consensus guidance on lipid testing and reporting in the United Kingdom has been endorsed by HEART UK and The Association for Laboratory Medicine.
No takes yet. Share an insight, caveat, or question.
Kenkre et al. (2025) conducted a review in Atherosclerotic cardiovascular disease. Consensus guidance on lipid testing and reporting was evaluated. Consensus guidance by UK experts recommends a standard lipid profile, enhanced testing with apolipoprotein B and lipoprotein (a), and the Sampson-NIH calculation for LDL-c estimation.
Synapse has enriched 10 related papers. Consider them for comparative context: